Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Newegg Commerce Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Newegg Commerce Inc trades at $10.79 (market cap $232.74M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 12.3× Newegg Commerce Inc's market cap, and Newegg Commerce Inc is more actively traded (40,856 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Newegg Commerce Inc for 14 Days on average.
| DYN | NEGG | |
|---|---|---|
Market Cap | $2.86B | $232.74M |
Volume | 3,341,579 | 40,856 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $92.74 |
52-Week Low | $14.60 | $10.61 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $2.18B | $202.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
NEGG trades at $10.61, down 6.52% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported revenue of $1.44 billion in 2025 with a net loss of $4.88 million, though recent quarters have beaten EPS estimates. Valuation ratios show a low P/S of 0.17 but a P/E of 24.52, while cash flow trends indicate reliance on financing activities. Recent news highlights partnerships with Western Digital and Hewlett Packard Enterprise to support IT infrastructure.
The outlook is mixed: improving profitability and strategic partnerships offer upside, but persistent net losses, negative operating cash flow, and insider selling pose risks. Analyst consensus is Buy with a $7.75 price target, below the current price, suggesting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
